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Long-term effects of antihypertensive regimens on renal hemodynamics
and proteinuria. The long-term effects of different antihypertensive
regimens were studied in uninephrectomized beagles with alloxan-
induced diabetes mellitus. Mean arterial pressure (MAP) was elevated
(P < 0.05) in untreated diabetic dogs. Treatment of diabetic dogs with
an angiotensin converting enzyme inhibitor (ACEI; lisinopril), a cal-
cium antagonist (CA; TA-3090), or both lowered MAP. At one year, the
RBF, GFR, and SNGFR were similarly elevated (P <0.05) in all groups
of diabetic dogs. The increase in SNGFR present in untreated diabetic
dogs was primarily attributable to an increased (P < 0.05) glomerular
capillary pressure (P0w). Treatment with lisinopril lowered the P0c to a
mean value that was indistinguishable from that for nondiabetic dogs. In
contrast, diabetic dogs treated with TA-3090 had an elevated PGC
While untreated diabetic dogs exhibited marked increases in glomerular
volume (P < 0.05 vs. nondiabetic dogs), treatment with lisinopril and
TA-3090, either alone or in combination, blunted the extent of glomer-
ular hypertrophy observed in diabetic dogs (P < 0.05 vs. untreated
diabetic dogs). Proteinuria was similarly reduced (P < 0.05 vs. un-
treated diabetic dogs) in dogs treated with lisinopril and TA-3090.
Combination therapy of diabetic dogs produced a further significant (P
<0.05) decrement in proteinuria. We conclude that although treatment
of diabetic dogs with either lisinopril or TA-3090 results in differential
effects on GC; each produces a similar decrement in proteinuria.
Further, combination therapy has a greater effect on proteinuria than
either agent alone. These data suggest that CA and ACE! have different
effects on renal hemodynamics in diabetic dogs and, further, that both
glomerular hypertension and glomerular hypertrophy are involved in
the proteinuria observed in diabetic dogs.
Progressive glomerulopathy associated with proteinuria and
systemic hypertension is a leading cause of renal failure and
death in diabetic human beings [1—51. It has been proposed that
changes in glomerular structure and function observed in dia-
betic individuals are responsible for the genesis and/or progres-
sion of renal injury [2—4, 6]. This hypothesis is supported by
studies with rodent models of diabetic renal disease in which
elevations of glomerular capillary pressure (PGC) and/or glomer-
ular volume have been causally associated with progressive
destruction of renal tissue [7—12].
Several studies demonstrate that angiotensin-converting en-
zyme inhibitors (ACE!) preserve glomerular structure and
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function in rodent models of diabetes [8—1 1]. The administration
of ACE! to rats with streptozotocin-induced diabetes consis-
tently lowers P and albuminuria [8, 9, 11]. The use of ACE!
may also attenuate glomerular hypertrophy in diabetic rats [9],
although this effect has not been consistently observed [11].
Conversely, studies with calcium antagonists (CA) have dem-
onstrated variable results in rats [10—151. In uninephrectomized
rats with streptozotocin-induced diabetes, the dihydropyridine-
type CA nifedipine lowered arterial pressure but failed to
reduce glomerular pressure and albuminuria, and did not pre-
vent glomerulosclerosis [11]. The absence of effect on glomer-
ulosclerosis and albuminuria has been noted with other dihy-
dropyridine-type CA [12, 13]. Studies with papaverine- or
benzothiaprine-type CA demonstrate variable effects on renal
hemodynamics and/or proteinuria in diabetic rats [10, 14, 15].
Thus the relative ability of CA to attenuate progression of
diabetic renal disease is inconsistent and may vary with the type
of CA used.
Although little is known about glomerular hemodynamics in
nonrodent animals with diabetes, changes in renal hemodynam-
ics observed in human beings with Type I diabetes parallel
those observed in rodent models of diabetes [3, 6, 16—19]. Overt
diabetic nephropathy in people is preceded by changes in renal
structure and function that include elevations of whole kidney
GFR [16—18] and glomerular size [17, 181. While effective
antihypertensive therapy may slow the rate of decline in GFR in
affected people [20, 211, the mechanism of this protection is not
well understood. In particular, the changes in glomerular he-
modynamics that occur in diabetic people and the effects of
antihypertensive therapy on these adaptations remain incom-
pletely characterized. While ACEI consistently lower protein-
uria in diabetic people [20-221, studies with dihydropyridine-
type CA indicate no effect or an increase in protein loss [23—25].
In contrast, studies with the benzothiaprine-type CA diltiazem
[24, 26, 27] or the use of the papaverine-type CA verapamil
alone or in combination with an ACE! [211 demonstrate a
reduction of proteinuria.
Glomerular structural changes were demonstrated in diabetic
beagles studied for one year after diabetes mellitus was induced
by alloxan administration [281. However, experimental studies
of the long-term effects of diabetes mellitus on renal function in
dogs have not been reported. Consequently, the effects of
diabetes on canine renal and glomerular function and the
hemodynamic effects of antihypertensive agents in this setting
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remain poorly characterized. The purpose of the current study
was to compare the effects of the chronic administration of an
ACEI (lisinopril) and a benzothiaprine CA (TA-3090), alone and
combined, on renal hemodynamics, glomerular volume, and
proteinuria in diabetic beagles.
Methods
General (Groups I to V)
Experiments were performed on 29 adult beagle dogs of
either sex weighing 13.0 0.3 kg. All dogs underwent right
nephrectomy. Twenty-three of these dogs received an intrave-
nous infusion of 60 mg/kg of alloxan to induce diabetes mellitus
[28]. The left renal artery was occluded during and for five
minutes after the infusion of alloxan to prevent acute tubular
necrosis. Control dogs (Group I) were studied in a manner
similar to the other groups. Dogs with diabetes mellitus were
randomly assigned to insulin therapy alone (Group II; N = 8),
insulin therapy plus daily oral administration of the ACEI
lisinopril (Group III; N = 6), insulin therapy plus daily oral
administration of the CA TA-3090 (Group IV; N = 5), or insulin
therapy plus combined daily oral administration of lisinopril and
TA-3090 (Group V; N = 4). The goal of insulin therapy was to
achieve a plasma glucose concentration in the range of 350 to
450 mg/dl immediately prior to the subsequent insulin dosage,
with adjustments of insulin dosage if results of several consec-
utive blood glucose determinations fell outside of this range. All
dogs were subsequently fed a diet which contained 15.4%
protein and 0.21% sodium (Hill's Pet Products, Topeka, Kan-
sas, USA). Quantities were adjusted to maintain stable body
weights. Plasma creatinine was assessed monthly. MAP was
measured in conscious dogs by direct femoral arterial puncture
at monthly intervals in treated dogs and every two months in
Group I. Dosages of antihypertensive agents were adjusted to
maintain MAP between 95 and 105 mm Hg.
Proteinuria and endogenous creatinine clearance (Groups I
to V)
Every two months during the study, the dogs were subjected
to 24-hour metabolism cage collections to quantify the degree of
proteinuria, and 24-hour endogenous creatinine clearance was
determined at four month intervals. Dogs were fed and admin-
istered their usual medications during these collections.
Renal hemodynamic studies (Groups I—IV)
Prior to these studies, the dogs were fasted for 16 to 20 hours.
The dogs were anesthetized with sodium pentobarbital (30
mg/kg i.v,) and were prepared for micropuncture and renal
clearance studies as previously described [29—31]. The trachea
was intubated and respiration was regulated mechanically (Har-
vard Apparatus, South Natick, Massachusetts, USA). A cath-
eter was placed in the left jugular vein. A solution containing
0.9% saline and 2.5% inulin was infused at a rate sufficient to
maintain a plasma inulin concentration of approximately 0.8
mg/mI in all dogs. Diabetic dogs received additional 0.9% saline
solution to replace excessive urinary losses during the proce-
dure. Arterial pressure was measured through a catheter in-
serted into the femoral artery. The catheter was connected to a
Statham pressure transducer (Statham Laboratories, Hato Rey,
Puerto Rico). Output was recorded on a Grass Polygraph (Grass
Instruments, Quincy, Massachusetts, USA). Blood samples
were also collected through this catheter.
The left kidney was exposed through a flank incision, and the
proximal renal artery and vein and the ureter were dissected
free of adjacent tissue. An electromagnetic flow transducer was
placed around the renal artery and connected to a square-wave
flowmeter (Carolina Medical Electronics, King, North Caro-
lina, USA) to measure renal blood flow (RBF). The ureter was
catheterized to allow timed urine collections.
An adjustable clamp was placed around the renal artery distal
to the flow probe or around the aorta proximal to the renal
artery in dogs with a short renal artery. A curved 23-gage needle
was placed in the renal artery distal to the lucite clamp and
connected to a Statham pressure transducer (Statham Labora-
tories) for measurement of renal arterial pressure (RAP). Ad-
justment of the vascular clamp allowed graded reductions in
RAP. The renal arterial line was infused with 0.2 mi/mm
heparinized, isotonic saline solution to maintain patency. The
left kidney was then placed on a Lucite holder and prepared for
micropuncture by removal of approximately 3 cm2 of the renal
capsule. This area was continuously bathed with warm (39°C),
heparinized, isotonic saline solution dripped through a quartz
rod, which was used to illuminate the micropuncture field.
Flexible tape was placed around the micropuncture field to
assist in stabilization. An agar well was placed around the
micropuncture field to maintain an isotonic saline solution pooi.
The remainder of the kidney was covered with warm, saline-
soaked gauze and loosely wrapped with plastic wrap.
Forty-five minutes later, micropuncture collections and mi-
cropressure measurements were made at spontaneous RAP.
The MAP, RAP, and RBF were continuously monitored, and
two or three timed ureteral collections of 15 to 20 minutes each
were made during these micropuncture studies for determina-
tion of inulin clearance (GFR). A blood sample was collected at
the midpoint of each timed urine collection. For SNGFR
determination, a sharpened pipette (12 to 18 j.tm tip) was filled
with Sudan black-stained castor oil. The pipette tip was inserted
into a proximal tubule, and an oil column of at least 5 tubule
diameters was inserted. Gentle aspiration was applied to initiate
the collection and to maintain the oil block in a constant
position. Timing was started at the initiation of collection and
continued for one to two minutes. After removal, the pipette
was stored in mineral oil prior to determining the volume and
inulin concentration of the collection. Hydraulic pressures were
determined by a micropressure servo-null system (Instrumen-
tation for Physiology and Medicine, San Diego, California,
USA). At least three free-flow proximal tubular pressures
(PTP), stop-flow proximal tubule pressures (SFP), and peritu-
bular capillary pressures (PCP) were measured for each dog.
The PCP measurements were taken from the earliest accessible
site on the cortical surface of the kidney.
Autoregulation studies (Groups I to IV)
Following clearance and micropuncture studies at spontane-
ous renal perfusion pressure, RAP was reduced to approxi-
mately 100 mm Hg and measurements were repeated. At the
end of each experiment, the electromagnetic flow probe was
calibrated in situ by the placement of a catheter directly into the
renal artery and collection of timed blood samples into a
graduated cylinder.
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Glomerular volume determinations (Groups I to V)
Formalin fixed tissue was processed by routine histologic
methods, and sections were stained with periodic acid-Schiff
and hematoxylin dyes. Planar area of 50 outer cortical glomer-
ular tufts, which were chosen randomly, were measured in
these sections with a planar morphometry image analysis sys-
tem (Southern Micro Instruments, Atlanta, Georgia, USA) to
determine glomerular volume as previously described [30]. The
morphometry system was calibrated with a micrometer reticle
(Reichert Scientific Instruments, Buffalo, New York, USA).
Analyses and calculations
Inulin concentration in both ureteral urine and plasma was
measured by an anthrone colorimetric technique [30]. Whole
kidney GFR was calculated by the standard clearance formula.
Microhematocrit (HCT) measurements were performed on all
arterial blood samples. Renal plasma flow (RPF) was derived
from the measured values for RBF and HCT. Whole kidney
filtration fraction (FF) was determined from GFR and RPF.
Measurements of sodium and potassium concentrations (Instru-
mentation Laboratory, Lexington, Massachusetts, USA) and
osmolality (Wescor, Logan, Utah, USA) were performed on all
urine and plasma samples. Plasma colloid osmotic pressure was
measured with a membrane osmometer (Wescor). Urine protein
concentration was determined by the Coomassie brilliant blue
technique [32].
Monthly glucose determinations and plasma and urine con-
centrations of creatinine were determined by a semi-automated
method (Beckman Instruments, Fullerton, California, USA).
Blood glucose concentration was assessed at least once weekly
with the use of reagent strips read by a semi-automated method
(Becton-Dickinson, Franklin Lakes, New Jersey, USA). Total
plasma glycosylated hemoglobin concentration was determined
by ion exchange chromatography (Isolab Incorporated, Akron,
Ohio, USA).
Tubular fluid inulin concentration was determined in dupli-
cate by a ultramicrofluorometric method [291. The SNGFR was
taken as the product of volume flow rate, determined with the
aid of constant bore tubing [29], and the tubular fluid-to-plasma
inulin ratio. Glomerular blood flow (GBF) and glomerular
plasma flow (GPF) were computed from the filtration fraction
(FF), single nephron glomerular filtration rate, and hematocrit:
GBF = SNGFRJ[FF(1 — HCT)J
GPF = SNGFR/FF
Whole kidney FF values were used for these calculations since
efferent arteriolar blood samples could not be obtained rou-
tinely during the study. Glomerular capillary pressure was
estimated from the sum of SFP and plasma colloid osmotic
pressure (ira). Single nephron vascular resistances, preglomer-
ular (RA), efferent arteriolar (RE), and total (RT) were estimated
by the expressions:
RA = (MAP — PGC)/GBF
RE (PGc — PCP)/(GBF — SNGFR)
RT = MAP/GBF
The glomerular ultrafiltration coefficient, K1, was calculated
using the integrated solution to the general differential equation
described previously [29—31],
where
and
Kf = (SNGFR/P) X [1 — A X ln(l — B)]
A = (R X ira)/[FF X AP X (R + Ira)]
B = [FF X AP X (R + ira)]I[R X (AP — ira)].
In these equations, AP is the glomerular transcapillary hydrau-
lic pressure gradient, ira is the afferent colloid osmotic pres-
sure, and R is a constant that relates ira to FF and efferent
colloid osmotic pressure (i). This approach is particularly
useful in the dog because the value of R (43) is affected only
slightly by variations in albumin-to-globulin ratios, which are
substantial in this species [29].
Following measurements at reduced renal perfusion pres-
sure, values for RBF obtained at spontaneous and reduced
renal perfusion pressure were compared. This comparison
allowed the determination of a renal autoregulatory index for
RBF for each dog, which was taken as the ratio of the percent
change in GFR divided by percent change in MAP. Autoregu-
latory indices for GFR were calculated in a similar manner.
Statistical analyses
Values are reported as means SEM. Data were compared
among groups by analysis of variance. Where a significant effect
was identified, group means were compared by the Fisher's
PLSD comparison test. A P value <0.05 was considered
indicative of a statistically significant difference.
Results
General (Groups I to V)
A comparable degree of hyperglycemia was present in all
groups of diabetic dogs (Fig. 1). Few changes in insulin dosage
were necessary after the first two months of the study, and the
mean insulin dosages were similar in the four diabetic groups,
averaging 0.9 0.1 U/kg in Group II, 0.9 0.1 U/kg in Group
III, 1.0 0.1 U/kg in Group IV, and 0.9 0.2 U/kg in Group V.
Glycosylated hemoglobin values were similarly elevated in all
groups of diabetic dogs (Table 1). For the final month of the
study, mean daily food intake values for Group 11(34.5 1.4
g/kg body wt/day), Group III (30.7 4.3 g/kg body wt/day),
Group IV (33.1 2.9 g/kg body wt/day), and Group V (34.8
5.1 g/kg body wt/day) were not different. However, the food
intake for all groups of diabetic dogs exceeded the correspond-
ing value for Group 1(21.0 1.3 g/kg body wt/day). There were
no significant differences in body weight among groups (Table
1).
Values for MAP in awake dogs (Fig. 2) indicated the presence
of mild systemic hypertension in the untreated diabetic dogs
(Group II) and a similar, modest reduction of MAP in all treated
groups (Groups III, IV, and V). At the time of renal hemody-
namic studies, directly measured MAP was significantly ele-
vated in Group II only. During the study, dosages of the
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Table 1. Systemic and renal parameters in dogs 1 year after the induction of diabetes mellitus
Group N
Body weight
kg
Hb A1
%
Scr BUN Hct
%
TP
g/dlmgldl
Group 1 6 13.2 0.7 6.9 0.3 1.3 0.1 13.3 0.9 39.7 2.6 5.9 0.2
Group II 8 13.6 0.5 9.8 0.4a 0.7 0.1 13.4 1.5 43.0 1.8 6.5 0.3
Group III 6 14.0 0.8 9.6 Q,5a 0.8 o.la 14.8 1.5 40.7 1.7 6.3 0.3
Group IV 5 12.9 1.4 9.7 1.Oa 0.9 0.la 12.6 3.0 40.8 1.2 6.8 0.5
Group V 4 12.3 0.6 9.5 1.Oa 0.9 o.la 11.0 1.3 41.2 2.5 6.2 0.3
Values are means SEM. Abbreviations are: Hb A1, total glycosylated hemoglobins; 5Cr' serum creatinine; BUN, blood urea nitrogen; Hct,
hematocrit; TP, arterial plasma total protein content.
P < 0.05 vs. Group I
Table 2. Results of renal clearance studies 1 year after the induction of diabetes mellitus in dogs
Group N
Plasma glucose
mgld!
MAP
mm Hg
RBF GFR FF
%
UV
mi/mmmi/mm/kg body wt
Group I 6 96 2 116.0 5.7 11.5 0.8 1.90 0.04 28 2 0.3 0.1
Group II
Group III
8
6
388 28379 21 126.0119.5 6.96.7 16.8 1.618.0 2.l' 3.20 0.37a2.86 0.36k'
33
27
ia 0.9 o.2
1.1 o.la
Group IV 5 364 554 116.2 5.3 17.3 2.6a 3.07 0.3la 31 3 1.2 0.3
Values are means SEM. Abbreviations are: MAP, mean arterial pressure; RBF, renal blood flow; GFR, glomerular filtration rate; FF, filtration
fraction; UV, urine flow.
a P < 0.05 vs. Group Ib P < 0.05 vs. Group II
(Fig. 3). Compared to Group I, the mean final serum creatinine
concentration was significantly reduced in all four groups of
diabetic dogs (Table 1). These final values were not different
from the mean values for serum creatinine (mg/dl) obtained in
the first month of the study: 1.2 0.3 (Group I), 0.8 0,1
(Group II), 1.0 0.7 mg/dl (Group III), 0.9 0.1 (Group IV),
and 0.8 0.1 mgldl (Group V). There were no significant
differences among groups in blood urea nitrogen concentration,
hematocrit, or plasma total protein concentration (Table 1).
Renal hemodynamic studies (Groups I to IV)
0' . . .
0 2 4 6 8 10 12
Time, months
Fig. 1. Serial values for blood glucose (BG) measurements in dogs.
Serial values for BG in control dogs (0, Group I, N = 6), untreated
diabetic dogs (•, Group II, N = 8), or diabetic dogs treated with
lisinopril (0, Group III, N = 6), TA-3090 (A, Group IV, N = 5), or both
(U, Group V, N = 4). Compared to control dogs, values for BG were
comparably elevated (P < 0.05) in all groups of diabetic dogs. Values
for Groups I and II are means SEM. For Groups III to V only means
are depicted. < 0.05 verses Groups II to V.
antihypertensive agents averaged 0.7 mg lisinopril/kglday and
15.7 mg TA-3090/kg/day.
Endogenous creatinine clearance was not significantly differ-
ent among groups of diabetic dogs at any time point in the study
and the mean value in all groups of diabetic dogs was signifi-
cantly (P < 0.05) greater than that in Group I at 8 and 12 months
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During renal clearance and micropuncture studies conducted
at spontaneous RAP in Groups I to IV (Table 2), the plasma
glucose concentration was similarly elevated in the three groups
________________________________________
of diabetic dogs. The RBF and GFR were also significantly
in Groups II, III, and IV. Dogs in Groups III and IV
exhibited intermediate values for GFR and RBF which were not
significantly different from untreated diabetics. Compared to
Group I, dogs of Group II exhibited a significant elevation in
FF. The chronic administration of lisinopril to diabetic dogs
(Group III) resulted in a value for FF that was significantly (P <
0.05) lower than that observed in untreated diabetic dogs
(Group II) but not different from the mean value for dogs of
Group I. All three groups of diabetic dogs exhibited a compa-
rable elevation in urinary flow rate.
Micropuncture studies (Table 3) indicated that SNGFR of
outer cortical nephrons was elevated (P < 0.05) in untreated
diabetic dogs, with a mean increase of 63%. A similar degree of
hyperfiltration was observed in Groups III and IV. Compared to
Group I, Group II exhibited a lower mean free-flow proximal
tubule pressure and an elevation in SFP, resulting in a signifi-
cant increment in both P0 and AP. Group III dogs exhibited
mean values for SFP, P, and zP that were reduced from
those observed in Group II and indistinguishable from values
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Time, months
Fig. 2. Serial values for mean arterial pressure (MAP) measurements
in awake dogs. Serial values for MAP in control dogs (0, Group I, N =
6), untreated diabetic dogs (•, Group II, N = 8), or diabetic dogs
treated with lisinopril (LI, Group III, N = 6), TA-3090 (A, Group IV, N
= 5), or both (U, Group V, N = 4). Compared to control dogs, values
for MAP were mildly elevated (P <0.05) in untreated diabetic dogs and
comparably lowered in Groups 111 to V. Values for Groups I and II are
means SEM. For groups III to V only means are depicted. *D < 0.05
verses Group I.
for Group I. Compared to Group II, dogs treated with TA-3090
(Group IV) exhibited significantly increased free-flow PTP, but
there was no significant difference between Groups II and IV in
SFP, GC, or P. There were no significant differences in PCP
or ira among groups.
Total renal vascular resistance (RT) was 0.39 0.05 nI
min' mm Hg in Group I and was reduced (P < 0.05) to a
mean value of 0.29 0.02 nI min' mm Hg' in Group II,
0.24 0.01 nl min1 mm Hg' in Group III, and 0.26 0.04
nl min'1 mm Hg in Group IV. Mean values for RA (Table
3) in Groups II to IV were less than (P < 0.05) the correspond-
ing value in Group I. The differences in mean values for RT and
RA between treated and untreated diabetic dogs did not reach
statistical significance. Chronic administration of the ACEI,
lisinopril, led to a mean value for RE in Group III that
represented a 30% reduction (P < 0.05) from that observed in
Group II. Although there was a trend for K1 to increase in both
treated groups, the K1 did not differ significantly among groups.
Autoregulation studies (Groups I to IV)
Following renal micropuncture studies, renal autoregulatory
capability was assessed. Initial measurements of GFR and RBF
were made at spontaneous values for MAP (Table 1). In dogs in
which spontaneous MAP exceeded 100 mm Hg, the RAP was
reduced to approximately 100 mm Hg and clearance measure-
ments were repeated. These studies were conducted at similar
mean values for MAP of 99.5 2.4 mm Hg in Group I (N = 5),
104.6 2.0mm Hg in Group II (N 7), 100.1 2.2mm Hg in
Group III (N = 5), and 103.8 1.5 mm Hg in Group IV (N =
4). At the reduced RAP, mean values for RBF and GFR were:
11.7 0.7 and 1.84 0.06 mi/mm/kg body wt in Group I, 15.9
E
00
1.0
Time, months
Fig. 3. Serial values for endogenous creatinine clearance (Cc,.) mea-
surements in dogs. Serial values for Ce,. in control dogs (0, Group I, N
= 6), untreated diabetic dogs (•, Group II, N = 8), or diabetic dogs
treated with lisinopril (LI, Group III, N = 6), TA-3090 (A, Group IV, N
= 5), or both (U, Group V, N = 4). Compared to control dogs, values
for Ce,. were elevated (P < 0.05) in all 4 groups of diabetic dogs. Values
for Groups I and II are means SEM. For groups III to V only means
are depicted. F < 0,05 versus Groups Il to V.
Fig. 4. Renal autoregulato,y indices. Values for renal autoregulatory
indices for renal blood flow (RB F) and glomerular filtration rate (GFR)
in control dogs (LI, Group I, N = 6), untreated diabetic dogs (, Group
II, N = 8), or diabetic dogs treated with lisinopril (0, Group III, N =
6) and TA-3090 (, Group IV, N = 5). Compared to Group I, renal
autoregulatory efficiency for both RBF and GFR was reduced in Groups
II to IV. Values are means SaM. < 0.05 versus Group I.
1.6 and 3.06 0.37 ml/min/kg body wt in Group II, 16.9 2.5
and 2.70 0.38 mi/mm/kg body wt in Group III, and 14.0 2.0
and 2.57 0.28 ml/minlkg body wt in Group IV. Autoregulation
of GFR and RBF was assessed by determination of the auto-
regulatory index, which represents the ratio of % change in
measured parameter (RBF or GFR) divided by % change in
MAP. An autoregulation index of 0 indicated perfect autoregu-
lation, and an index of 1.0 indicated a lack of autoregulation and
a passive relationship between MAP and RBF or GFR. These
results indicated a reduced capability to autoregulate RBF and
E
E
0
100
3.0
2.0
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Table 3. Results of micropuncture studies 1 year after the induction of diabetes mellitus in dogs
Group N
SNGFR
ni/mm
SFP PTP PCP lTa
mm Hg
Group I
Group II
Group III
Group IV
6
8
6
5
52.1 3.6
85.1 8.P
80.7 54a
82.3 37a
37.5 2.045.4 l.5
37.1 17b
45.1 2.1C
18.0
13.6
13.7
18.2
1.41.l
l.5a
l.6'°
8.1 0.7
7.0 0.7
8.5 0.6
8.9 1.2
16.0 0.6
17.9 0.5
17.8 0.7
18.0 0.6
54.3
62.8
55.1
63.4
2.0
1.7
1•9b
1.l°
Values are means SEM. Abbreviations are: SNGFR, single nephron glomerular filtration rate; SFP, proximal tubule stop-flow pressure; PTP,
proximal tubule free-flow pressure; a, afferent colloid osmotic pressure; P, glomerular capillary hydrostatic pressure; zP, glomerular
transcapillary hydrostatic pressure gradient; RA, afferent arteriolar resistance; R, efferent arteriolar resistance; Kf, glomerular ultrafiltration
coefficient.
a P < 0.05 vs. Group Ib P < 0.05 vs. Group II
P < 0.05 vs. Group III
Fig. 5. Serial values for daily urinary protein
excretion (U,.,1V) in awake dogs. Serial
values for Up 0V in control dogs (Li, Group 1,
N = 6), untreated diabetic dogs (, Group II,
N = 8), or diabetic dogs treated with lisinopril
(U, Group III, N = 6), TA-3090 (, Group
IV, N = 5), or both (, Group V, N = 4).
Compared to control dogs, values for UprotV
were elevated (P < 0.05) in untreated diabetic
* dogs. The rise in proteinuria was attenuated in
+ Groups III to V. Moreover, combination
therapy resulted in the greatest attenuation of
proteinuria in Group V. Values are means
SEM. < 0.05 versus baseline, tP < 0.05
versus all other groups, tP < 0.05 versus
Group II.
GFR in Group II (Fig. 4). While chronic converting enzyme
inhibition (Group III) had no apparent additional effect on renal
autoregulation, dogs in Group IV exhibited a nonsignificant
trend for a further decrement in renal autoregulatory capability.
Glomerular volume determinations (Groups I to V) I)
The mean glomerular volume was 3.52 0.13 X 106j.t3 in
Group I. Glomerular enlargement was observed in all four
groups of diabetic dogs (P < 0.05). However, compared to the
mean glomerular volume in Group II of 6.14 0.30 x 106,.3,
treatment of diabetic dogs with lisinopril, TA-3090, or both
significantly (P < 0.05) limited the extent of glomerular hyper-
trophy and corresponding values for mean glomerular volume
were 4.57 0.36 x 106p3 in Group III, 4.74 0.27 x 106jr3 in
Group IV, and 4.55 0.86 x 106p3 in Group V.
Proteinuria (Groups I to V)
Significant increments in proteinuria were present in Group II
at all time points (Fig. 5). Treatment with lisinopril and TA-3090
attenuated the increase of proteinuria to a value that was not
significantly different from the mean value in Group I. Interest-
ingly, dogs treated with combination therapy (Group V) exhib-
ited a further decrement (P < 0.05) in urinary protein excretion.
Furthermore, the mean value in this group was significantly less
than that observed in uninephrectomized control dogs (Group
Discussion
Diabetes mellitus induced in dogs by alloxan administration
was associated with moderate hyperglycemia, systemic hyper-
tension, and significant changes in renal function. Compared to
controls, untreated diabetic dogs exhibited whole organ hyper-
perfusion and hyperfiltration. Micropuncture measurements in
outer cortical nephrons demonstrated single nephron hyperfil-
tration in untreated diabetic dogs which was attributable to a
fall in preglomerular vascular resistance and a resultant in-
crease in P0 and P. These hemodynamic changes were
accompanied by glomerular hypertrophy and substantial pro-
teinuria. Treatment with lisinopril, TA-3090, or both led to
modest, comparable reductions in MAP among the treated
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Table 3. Continued
P
mm Hg
DA DE Kf.jm1min
mm Hg'mm Hg• mm n11
36.3 2.0 0.205 0.027 0,186 0.023 3.53 0.40
49.3 2.Oa 0.142 0.014a 0.159 0.012 3.61 0.32
41.4 14b 0.126 o.olla 0.110 0007a,b 4.53 0.48
45.2 l.2 0.120 0.018a 0.153 0.021 4.12 0.23
diabetic dogs. All treatment regimens were associated with
significant reductions in the extent of glomerular hypertrophy
and proteinuria, without significantly lowering RBF, GFR, or
SNGFR.
Therapy with either lisinopril or TA-3090 alone, however,
had contrasting effects on glomerular hydraulic pressures. The
chronic administration of lisinopril to diabetic dogs produced a
decrement in postglomerular resistance which led to a reduction
in both GC and P to values similar to those observed in
nondiabetic control dogs. Similarly, previous studies in rats
have consistently demonstrated that ACEI administration low-
ers P0 in diabetic rats and in rats with reduced renal mass [8,
9, 11]. A recent study indicated no effect of the dihydropyri-
dine-type CA nifedipine on GC in diabetic rats [11]. While
treatment of diabetic dogs with TA-3090 similarly had no
apparent effect on in diabetic dogs, this CA did produce a
significant increase in free-flow PTP, resulting in a value for P
that was reduced, albeit not statistically different, from the
mean value for P observed in untreated diabetic dogs. A
similar differential effect of CA on P0 and P has been
associated with renoprotection in rats with reduced renal mass
[33]. In contrast, treatment of diabetic rats with the CA nife-
dipine produced a similar increment in proximal tubular free-
flow pressure without reducing GC, i.P, or the extent of
glomerular injury [11]. The mechanism responsible for varia-
tions in PTP in the dogs of this study is unknown.
The different effects of lisinopril and TA-3090 on glomerular
capillary pressure were attributed to effects of these agents on
segmental renal resistances. Diabetic dogs treated with lisino-
pril, but not TA-3090, exhibited a substantial decrement in
postglomerular resistance. Although both antihypertensive
agents tended to produce a decrement in afferent arteriolar
tone, neither of these trends was statistically significant. Previ-
ous studies in normal dogs provide evidence for a differential
effect of acutely administered CA and ACE! on segmental renal
vascular resistances, with CA preferentially lowering preglo-
merular vascular resistance [34] and ACEI producing afferent
and efferent vasodilation [35, 36]. Apparently contrasting re-
suits were obtained in one study which indicated that diltiazem
and verapamil lowered PGC in partially nephrectomized rats
[37]. However, the fall in GC in CA treated rats of that study
was attributable to a marked decline (45 mm Hg) in MAP
rather than to a preferential lowering of RE. In contrast,
treatment of diabetic dogs with CA in the current study pro-
duced a comparatively mild decrement in MAP coupled with
the absence of a significant effect on RE and consequently the
CA did not alter Gc
We demonstrated an impairment of renal autoregulatory
control of RBF and GFR above 100 mm Hg in diabetic dogs.
Although limited, these studies are consistent with findings in
normal dogs during intrarenal infusion of glucose [38]. Studies
in diabetic rats have provided conflicting evidence of either
impaired [39] or enhanced [40] RBF autoregulation. The alter-
ations of renal autoregulation in diabetic animals may, in part,
be due to a failure of myogenic vasoconstriction [41] or to an
alteration in the macula densa feedback signal [38].
Many studies of single nephron hemodynamics in diabetic
animals have been conducted in Munich-Wistar rats, primarily
because of the availability of superficial glomeruli for direct
micropuncture measurement of GC In the dog, superficial
glomeruli are rarely available, so proximal tubule SFP is
generally used to estimate GC [29, 30, 42, 43]. Canine GC
estimated from SFP measurements are, in general, slightly
higher than the direct measurements of GC in this species
[43—45]. Similarly, SNGFR determined by total proximal col-
lection results in an overestimation of true SNGFR, as assessed
by distal collections [46]. Since the current study employed the
same technique to measure P and SNGFR in all dogs studied
by micropuncture, it is unlikely that methodological consider-
ations could account for the observed differences.
Several factors may have contributed to observed reductions
in proteinuria in the treatment groups. Dogs chronically treated
with lisinopril exhibited a reduction in MAP, P0, P, and
glomerular volume associated with a decline in proteinuria. The
attenuation of proteinuria and preservation of glomerular struc-
ture in diabetic rats has been causally associated with the
lowering of P and/or P observed in rats chronically treated
with ACE! [8—11]. However, monotherapy of diabetic dogs
with CA produced a decrement in proteinuria that was similar
to that observed in diabetic dogs treated with lisinopril and
associated with a significant reduction in glomerular volume
and MAP but with no effect on P0. These results do not,
however, determine whether the observed proteinuria was
associated with structural glomerular lesions or alterations in
glomerular basement membrane charge or size selectivity.
While glomerular hypertension and a loss of renal autoregu-
latory capability were observed in diabetic dogs, this study did
not investigate the long-term consequences of the observed
changes in renal hemodynamics. Within the time course of the
current study, diabetic dogs demonstrated a temporal pattern of
increasing hyperfiltration. The lack of progressive decrements
of GFR is not surprising, since previous studies in nondiabetic
dogs indicate that a similar degree of glomerular hypertension
does not produce rapid decrements in GFR [30, 47—53], sug-
gesting that the hypertensive canine glomerulus may be less
susceptible than that of rodents to the development of glomer-
ulosclerosis. However, our studies demonstrated increased
proteinuria in diabetic dogs and further showed that the extent
of the proteinuria was reduced by antihypertensive therapy.
In summary, diabetic dogs exhibited systemic hypertension,
proteinuria, glomerular hyperfiltration, glomerular hyperten-
sion, glomerular hypertrophy, and a loss of renal autoregulatory
capability. Dogs treated with lisinopril had normalization of
arterial and glomerular capillary pressures and glomerular vol-
ume. Treatment with TA-3090 resulted in equivalent control of
arterial pressure and glomerular volume but had no apparent
effect on P0. Treatment of diabetic dogs with the CA did
attenuate the rise in proteinuria to a similar extent as the ACEI.
Lastly, combining the two antihypertensive agents resulted in
the greatest antiproteinuric effect. In these diabetic dogs, there
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was an association between the extent of glomerular enlarge-
ment and proteinurja. However, these data demonstrate a
dissociation between extent of proteinuria and control of GC•
Our results are consistent with the concept that ACE! and CA
have different effects on renal hemodynamics and, further, that
the attenuation of proteinuria in diabetics treated with antihy-
pertensive agents is not solely dependent upon a reduction in
glomerular capillary pressure.
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